Memo Therapeutics
高管
查看带有其 16 名主要高管的组织结构图
Memo Therapeutics 搜索最多的简介
高管在Memo Therapeutics变化
- Frits Van Alphen已作为Chief Development Officer加入公司 (新闻发布的2024十一月5号).
- Gerald Parzmair, Senior Vice President, Development, 已经离开公司 (新闻发布的2024十一月5号).
- Alex Bastian已作为Vice President, Commercial Strategy加入公司 (新闻发布的2024八月29号).
创建提醒
跟踪 Memo Therapeutics 的高管变动
生物技术
Memo Therapeutics 拥有 2,327 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Chromocell的新名称是Channel Therapeutics Corporation。 (公布2024十一月22号).
- Enveda Biosciences 刚刚宣布为 130 筹款数百万美元。 (公布2024十一月22号).
- Alentis Therapeutics 刚刚宣布为 181 筹款数百万美元。 (公布2024十一月20号).
生物技术 行业的其他推荐联系人
消息
Memo Therapeutics 的最新新闻稿
- Memo Therapeutics AG appoints Paul Carter as Chairperson - Memo Therapeutics AG
- Memo Therapeutics increases Series C financing to CHF 45 million - Memo Therapeutics AG
- Memo Therapeutics AG Strengthens Management Team - Memo Therapeutics AG
- Memo Therapeutics AG Appoints Erik van den Berg as Chief Executive Officer - Memo Therapeutics AG
- Memo Therapeutics AG Raises CHF 25 Million Series C Financing to Complete Phase II Clinical Development of AntiBKV for BKV Infection in Renal Transplant Patients - Memo Therapeutics AG
- MEMO THERAPEUTICS AG PRESENTED AT SWISS NORDIC BIO 2017 IN ZURICH - Memo Therapeutics AG
- Memo Therapeutics AG Starts U.S. Pivotal Phase II/III Clinical Trial with AntiBKV for Treatment of BKV Infection in Renal Transplant Patients - Memo Therapeutics AG
- Memo Therapeutics AG Receives FDA Fast Track Designation for AntiBKV as Treatment of BKV Infection in Renal Transplant Patients - Memo Therapeutics AG
- Memo Therapeutics AG Announces Positive Phase I Data with AntiBKV for Treatment of BKV Infection in Renal Transplant Patients - Memo Therapeutics AG
- Memo Therapeutics AG and Ono Pharmaceutical Enter Antibody Discovery Partnership for Immuno-oncology Targets - Memo Therapeutics AG
- View more press releases Close
通过电子邮件
